Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle D Hackshaw

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Breast Cancer (Tokyo, Japan)|September 8, 2022
Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment studyCarol Mansfield, Willings Botha, Gerard T Vondeling, et al.
Journal of Managed Care & Specialty Pharmacy|March 23, 2016
Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage MembershipLesley-Ann Miller, Stephen Stemkowski, Kim Saverno, et al.
Clinical Genitourinary Cancer|December 16, 2014
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology SettingNicholas J Vogelzang, Michelle D Hackshaw, Thomas E Hutson, et al.
Cancer Treatment and Research Communications|July 17, 2020
Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of TrastuzumabMichelle D Hackshaw, Christine L Bui, Amy Ladner, et al.
Sarcoma|April 1, 2014
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology networkClara Chen, Rohit Borker, James Ewing, et al.
Journal of Managed Care & Specialty Pharmacy|January 7, 2015
Health care costs among renal cancer patients using pazopanib and sunitinibRyan N Hansen, Michelle D Hackshaw, Saurabh P Nagar, et al.
Breast Cancer Research and Treatment|May 19, 2022
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature reviewEdith A Perez, Chau Dang, Caleb Lee, et al.
Sarcoma|January 24, 2014
Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US PopulationMei Sheng Duh, Michelle D Hackshaw, Jasmina I Ivanova, et al.
BMC Cancer|August 29, 2021
Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature reviewMichelle D Hackshaw, Heather E Danysh, Mackenzie Henderson, et al.
Breast Cancer Research and Treatment|June 28, 2020
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancerMichelle D Hackshaw, Heather E Danysh, Jasmeet Singh, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Breast Cancer (Tokyo, Japan)|September 8, 2022
Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment studyCarol Mansfield, Willings Botha, Gerard T Vondeling, et al.
Journal of Managed Care & Specialty Pharmacy|March 23, 2016
Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage MembershipLesley-Ann Miller, Stephen Stemkowski, Kim Saverno, et al.
Clinical Genitourinary Cancer|December 16, 2014
First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology SettingNicholas J Vogelzang, Michelle D Hackshaw, Thomas E Hutson, et al.
Cancer Treatment and Research Communications|July 17, 2020
Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of TrastuzumabMichelle D Hackshaw, Christine L Bui, Amy Ladner, et al.
Sarcoma|April 1, 2014
Epidemiology, treatment patterns, and outcomes of metastatic soft tissue sarcoma in a community-based oncology networkClara Chen, Rohit Borker, James Ewing, et al.
Journal of Managed Care & Specialty Pharmacy|January 7, 2015
Health care costs among renal cancer patients using pazopanib and sunitinibRyan N Hansen, Michelle D Hackshaw, Saurabh P Nagar, et al.
Breast Cancer Research and Treatment|May 19, 2022
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature reviewEdith A Perez, Chau Dang, Caleb Lee, et al.
Sarcoma|January 24, 2014
Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US PopulationMei Sheng Duh, Michelle D Hackshaw, Jasmina I Ivanova, et al.
BMC Cancer|August 29, 2021
Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature reviewMichelle D Hackshaw, Heather E Danysh, Mackenzie Henderson, et al.
Breast Cancer Research and Treatment|June 28, 2020
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancerMichelle D Hackshaw, Heather E Danysh, Jasmeet Singh, et al.
Pageof 3